Edgewise Therapeutics Reports Q4/FY25 Financial Results and Outlines Key Clinical Milestones for 2026
summarizeSummary
Edgewise Therapeutics reported its fourth quarter and full year 2025 financial results, including an increased net loss, but highlighted a strong cash position and provided a detailed outlook for multiple significant clinical trial milestones and data readouts expected throughout 2026.
check_boxKey Events
-
Q4 and Full Year 2025 Financial Results
Reported a net loss of $50.2 million ($0.47 per share) for Q4 2025, compared to $40.7 million ($0.39 per share) in the preceding quarter. R&D expenses increased to $43.6 million and G&A expenses rose to $12.4 million for the quarter.
-
Strong Cash Position
Ended December 31, 2025, with approximately $530.1 million in cash, cash equivalents, and marketable securities, providing significant operational runway.
-
Upcoming Clinical Data Readouts
Expects 12-week data from the CIRRUS-HCM trial of EDG-7500 in hypertrophic cardiomyopathy (HCM) and Phase 1 healthy adult trial data for EDG-15400 (heart failure) in the first half of 2026.
-
Pivotal Trial Results for Sevasemten
Anticipates top-line data from the pivotal GRAND CANYON trial for sevasemten in Becker muscular dystrophy in the fourth quarter of 2026, with a potential NDA submission planned for H1 2027.
auto_awesomeAnalysis
This 8-K filing provides a comprehensive update on Edgewise Therapeutics' financial performance and, more critically for a life sciences company, a detailed roadmap of its clinical pipeline. While the company reported an increased net loss for Q4 2025, its strong cash position of over $530 million provides a substantial runway for operations. The most significant aspect for investors is the clear articulation of multiple near-term catalysts, including several data readouts and trial initiations expected in 2026. These milestones are crucial for advancing its muscular dystrophy and cardiovascular programs and will be key drivers of investor sentiment and future valuation.
At the time of this filing, EWTX was trading at $30.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $10.60 to $31.82. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.